Britain and America have signed a major trade agreement that will ensure no duties on British drug shipments going into the American market.
Key Provisions of the Accord
As part of the deal, the UK has agreed to raise expenditure on drugs through the NHS. This commitment secures that duties on these key goods will be held at nothing for a period of 36 months.
This development comes after earlier statements to significantly raise import taxes on branded pharmaceutical products, with increases discussed up to double the cost.
"This arrangement with the United Kingdom reinforces the worldwide climate for new treatments and introduces much-needed balance to American-British drug exports," a statement said.
Economic Significance
Drugs represent one of the the United Kingdom's most significant goods shipped to the United States, which is clearly the biggest destination for leading British pharmaceutical firms.
Trade data reveal that in the year to the end of September, the UK shipped pharmaceutical products valued at £11.1bn to the US. This figure represented 17.4% of all goods exports in that span.
"This deal safeguards work, boosts funding and sets the stage for the UK to establish itself as a international leader for life sciences," a minister commented.
Specific NHS Changes
The agreement involves several notable commitments from the United Kingdom:
- Revised Affordability Limit: The UK will raise the price threshold at which it considers new therapies to be too expensive by a quarter.
- Boosted Medicine Funding: There is a goal to double total health service expenditure on treatments from 0.3 percent of GDP to 0.6% over the coming ten years.
- Payback Limit: The amount drug companies must pay back to the NHS to stay within budget will be limited at fifteen percent. In the past, repayments exceeded 20%.
Broader Context
The pact follows a long-running tension between the drug companies and the British authorities over drug pricing and regulatory access.
The disagreement were intensified by arguments that American customers were charged significantly more for the identical medicines than people in the UK and Europe.
Recently, several major pharmaceutical investments in the UK have been delayed or abandoned, while major expansions have been announced toward American operations.
The Science Minister publicly accepted that the NHS needed to increase expenditure on drugs, noting that its budget allocation on drugs had shrunk as a percentage of its resources over the past decade.
